Experimental injection offers new hope for Treatment-Resistant lupus patients
NCT ID NCT07408336
Summary
This early-stage study is testing a new injection called AFN50 for people with autoimmune diseases, focusing on lupus that has returned or hasn't responded to standard treatments. Researchers want to see if AFN50 is safe and if it can help control lupus symptoms by measuring disease activity over 12 months. The study will enroll 18 adults whose lupus remains active despite current medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230001, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.